Abstract Library

#2792 Post-Transplant Recurrence of Neuroendocrine Tumors

Introduction: Recurrence after liver transplantation (LT) for metastases from NET is observed in 30-50% of cases at 5 years after LT but management is individualized

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Monteleone M, Sposito C, Rossi R, Pusceddu S, Coppa J,

Keywords: Liver transplantation, Recurrence, Liver metastases,

#2784 Predictive Factors of Tumor Recurrence after Radical Surgery for Gastro-Entero-Pancreatic Neuroendocrine Neoplasms (GEP-NENs): Identification of High-Risk Subgroups

Introduction: There is no proven role for adjuvant medical therapy after curative surgery (R0) for GEP-NENs.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Rossi R

Authors: Rossi R, Altomare M, Monteleone M, Prinzi N, Pusceddu S,

Keywords: radical surgery, recurrence, gastro-entero-pancreatic neuroendocrine neoplasms, prognostic factors,

#2736 Second Primary Neoplasms in Patients with Neuroendocrine Neoplasms (NEN): DATA from a Retrospective Multicentric Study

Introduction: Patients with sporadic gastro-entero-pancreatic neuroendocrine neoplasms (GEP-NEN) may exhibit a higher risk of second primary tumors than the general population.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Massironi S

Authors: Massironi S, Campana D, Pusceddu S, Albertelli M, Faggiano A,

Keywords: GEP-NEN, Second primary neoplasm (PMN), Overall survival (OS),

#2716 Neuroendocrine Carcinoma of the Upper Urinary Tract: A Case Report

Introduction: There are no dedicated guidelines for treatment of urothelial NEC given disease rarity. An aggressive approach, including neoadjuvant cisplatin-based chemotherapy + nephroureterectomy and adjuvant platinum-based chemotherapy, is recommended.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Rossi R

Authors: Rossi R, Monteleone M, Altomare M, Torchio M, Pusceddu S,

Keywords: Urothelial neuroendocrine carcinoma, chemotherapy, surgery, radiotherapy,

#2065 Sunitinib in Patients with Pre-Treated Pancreatic Neuroendocrine Tumors: A Real-World Study

Introduction: Besides data reported in a Phase-III trial, data on sunitinib in pancreatic Neuroendocrine Tumors (panNETs) are scanty.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Rinzivillo M

Authors: Rinzivillo M, Gritti S, Pusceddu S, Spallanzani A, Ibrahim T,

Keywords: Sunitinib, neuroendocrine tumors, pancreas, progressive disease, target therapy,